Congruence Therapeutics has secured a $32 million financing round to support the development of its lead candidate CGX-926, the first clinical therapy designed to treat MC4R-deficient genetic obesity. The proceeds will fund a Phase 1 trial in healthy volunteers and a Phase 1b proof-of-concept study in patients with MC4R-driven obesity, with a clinical trial application planned for the second half of 2025.
The financing attracted continued backing from all existing investors, including Amplitude Ventures, FSTQ, Lumira, Investissement Québec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria. Their renewed commitment highlights confidence in Congruence’s computational approach to correcting disease-causing protein misfolding.
Congruence applies its proprietary Revenir platform to capture the dynamic biophysical effects of genetic mutations and predict small molecules capable of restoring proper protein function. Beyond CGX-926, the company is advancing corrector programs for GBA1-linked Parkinson’s disease and alpha-1 antitrypsin deficiency toward development candidate nomination this year.
The company also maintains research collaborations with Ono Pharmaceuticals on multi-target oncology approaches and with an undisclosed partner to tackle a challenging metabolic target. These partnerships leverage Revenir to expand into new therapeutic areas and accelerate discovery.
With CGX-926 moving into human studies in early 2026, Congruence will generate its first clinical proof-of-concept data for genetic obesity. In parallel, late-stage preclinical testing will conclude for its Parkinson’s and A1AT deficiency programs, positioning multiple candidates for clinical advancement.
KEY QUOTES:
“This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options. We will also advance our programs in GBA-1 Parkinson’s Disease and Alpha-1 Antitrypsin Deficiency toward Development Candidate nomination this year.”
Dr. Clarissa Desjardins, CEO of Congruence
“Congruence is building a transformative pipeline of drugs it has discovered leveraging its powerful computational engine, Revenir. The team has demonstrated scientific rigor and capital efficiency in advancing these important medicines into late preclinical testing. We are proud to continue to support Congruence as it advances its lead program CGX-926 into clinical testing and inches closer towards its mission of treating diseases of high unmet medical need.”
Daniel Hétu, M.D., MBA, Managing Director at Lumira Ventures
“Too many patients with devastating genetic conditions have been left without effective treatments. Congruence’s small-molecule corrector approach offers new hope for people affected by MC4R-driven obesity, GBA Parkinson’s, A1AT deficiency and cancer. We are honored to support their mission through our investment in Congruence.”
Nancy Harrison, Venture Partner at Amplitude Ventures
